Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
Just over half of U.S. teens say they have used chatbots for help with schoolwork, and 12% say they’ve gotten emotional support from these tools. Teens tend to view the future impact of AI on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results